These results suggest that CREB3L1-deficiency could be a biomarker for metastatic cancers which could help identify patients at risk for treatment failure or early relapse, a group that may benefit from more aggressive treatment options or at least closer monitoring for disease recurrence. Here, CREB3L1 is linked to metastatic malignant neoplasm.